Taro Shareholder Value Creation and Strategic Overview
☐
☐
☐
☐
☐
☐
11
Haifa, Israel
Manufacturing, Research, Marketing & Distribution
Fully Compliant - Approved by FDA, IMH and
Accreditation of foreign manufacturing
API Development and Manufacturing
900,000 sq. ft. manufacturing facility
700+ employees
100+ finished dosage forms/250+ products
manufactured
ㅁ
Focus: oral solids, liquids, semi-solids and foams
Therapeutic Areas - Dermatology, Pain, Gastro,
Cardiology and Dental
Primary product lines:
◉
ㅁ
ㅁ
ㅁ
Dermatology: Rx and OTC semi-solid and liquid
products (creams, ointments, lotions & gels)
Cardiology and Neurology: Prescription oral
dosage products
Gastroenterology: Rx and OTC (Nexium,
Normalax & Meroken)
Oral analgesics: Rx and OTC
◉ Oral Central Nervous System (CNS): Rx
O O O O
◉
◉
OTC nasal sprays
Allergy (Antihistamine): OTC oral dosage
products
+$46M in salesView entire presentation